JP2012533546A5 - - Google Patents

Download PDF

Info

Publication number
JP2012533546A5
JP2012533546A5 JP2012520691A JP2012520691A JP2012533546A5 JP 2012533546 A5 JP2012533546 A5 JP 2012533546A5 JP 2012520691 A JP2012520691 A JP 2012520691A JP 2012520691 A JP2012520691 A JP 2012520691A JP 2012533546 A5 JP2012533546 A5 JP 2012533546A5
Authority
JP
Japan
Prior art keywords
acceptable salt
pharmaceutically acceptable
compound according
methyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520691A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012533546A (ja
JP5715127B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/041645 external-priority patent/WO2011008663A1/en
Publication of JP2012533546A publication Critical patent/JP2012533546A/ja
Publication of JP2012533546A5 publication Critical patent/JP2012533546A5/ja
Application granted granted Critical
Publication of JP5715127B2 publication Critical patent/JP5715127B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520691A 2009-07-15 2010-07-12 Gpr119アゴニスト Expired - Fee Related JP5715127B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09382114.8 2009-07-15
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
US61/245,445 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (3)

Publication Number Publication Date
JP2012533546A JP2012533546A (ja) 2012-12-27
JP2012533546A5 true JP2012533546A5 (US20040106767A1-20040603-C00005.png) 2013-08-08
JP5715127B2 JP5715127B2 (ja) 2015-05-07

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012520691A Expired - Fee Related JP5715127B2 (ja) 2009-07-15 2010-07-12 Gpr119アゴニスト

Country Status (24)

Country Link
US (1) US8207344B2 (US20040106767A1-20040603-C00005.png)
EP (1) EP2454251A1 (US20040106767A1-20040603-C00005.png)
JP (1) JP5715127B2 (US20040106767A1-20040603-C00005.png)
KR (1) KR101365854B1 (US20040106767A1-20040603-C00005.png)
CN (1) CN102471313B (US20040106767A1-20040603-C00005.png)
AR (1) AR077638A1 (US20040106767A1-20040603-C00005.png)
AU (1) AU2010273642B2 (US20040106767A1-20040603-C00005.png)
BR (1) BRPI1015921A2 (US20040106767A1-20040603-C00005.png)
CA (1) CA2764906C (US20040106767A1-20040603-C00005.png)
CO (1) CO6480977A2 (US20040106767A1-20040603-C00005.png)
CR (1) CR20120012A (US20040106767A1-20040603-C00005.png)
DO (1) DOP2012000006A (US20040106767A1-20040603-C00005.png)
EA (1) EA020540B1 (US20040106767A1-20040603-C00005.png)
EC (1) ECSP12011606A (US20040106767A1-20040603-C00005.png)
IL (1) IL216776A0 (US20040106767A1-20040603-C00005.png)
MA (1) MA33428B1 (US20040106767A1-20040603-C00005.png)
MX (1) MX2012000704A (US20040106767A1-20040603-C00005.png)
NZ (1) NZ597125A (US20040106767A1-20040603-C00005.png)
PE (1) PE20121045A1 (US20040106767A1-20040603-C00005.png)
SG (1) SG177646A1 (US20040106767A1-20040603-C00005.png)
TN (1) TN2012000002A1 (US20040106767A1-20040603-C00005.png)
TW (1) TWI429634B (US20040106767A1-20040603-C00005.png)
WO (1) WO2011008663A1 (US20040106767A1-20040603-C00005.png)
ZA (1) ZA201200227B (US20040106767A1-20040603-C00005.png)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CA2812061A1 (en) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012135570A1 (en) * 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
CA2831334A1 (en) 2011-04-08 2012-10-11 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EA031618B1 (ru) 2011-06-09 2019-01-31 Ризен Фармасьютикалз Са Соединения-модуляторы gpr-119
AU2012271009A1 (en) 2011-06-16 2013-11-14 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
US9422266B2 (en) 2011-09-30 2016-08-23 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
WO2013062838A1 (en) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
JP6101279B2 (ja) 2011-11-15 2017-03-22 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. Gpr119アゴニストとして有用な置換シクロプロピル化合物
MX365108B (es) 2012-06-12 2019-05-23 Chong Kun Dang Pharmaceutical Corp Derivados piperidina para agonista gpr119.
AR091739A1 (es) 2012-07-11 2015-02-25 Elcelyx Therapeutics Inc Composiciones y metodos para reducir el riesgo cardiometabolico
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
CN105873916B (zh) 2013-11-26 2019-08-27 株式会社钟根堂 用于gpr119激动剂的酰胺衍生物
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
EP4172162A1 (en) 2020-06-26 2023-05-03 Kallyope, Inc. Ampk activators

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20084540B (en) * 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
CA2660699A1 (en) 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2009038974A1 (en) * 2007-09-20 2009-03-26 Irm Llc Compounds and compositions as modulators of gpr119 activity

Similar Documents

Publication Publication Date Title
JP2012533546A5 (US20040106767A1-20040603-C00005.png)
JP2011529054A5 (US20040106767A1-20040603-C00005.png)
JP2009523760A5 (US20040106767A1-20040603-C00005.png)
JP2013510120A5 (US20040106767A1-20040603-C00005.png)
JP2013518107A5 (US20040106767A1-20040603-C00005.png)
JP2009502743A5 (US20040106767A1-20040603-C00005.png)
JP2012502037A5 (US20040106767A1-20040603-C00005.png)
JP2011502958A5 (US20040106767A1-20040603-C00005.png)
JP2011528658A5 (US20040106767A1-20040603-C00005.png)
JP2010265321A5 (US20040106767A1-20040603-C00005.png)
JP2009531376A5 (US20040106767A1-20040603-C00005.png)
JP2006143751A5 (US20040106767A1-20040603-C00005.png)
JP2012532874A5 (US20040106767A1-20040603-C00005.png)
JP2013508279A5 (US20040106767A1-20040603-C00005.png)
JP2012255026A5 (US20040106767A1-20040603-C00005.png)
JP2008533007A5 (US20040106767A1-20040603-C00005.png)
JP2013513621A5 (US20040106767A1-20040603-C00005.png)
JP2006526590A5 (US20040106767A1-20040603-C00005.png)
JP2009530345A5 (US20040106767A1-20040603-C00005.png)
JP2011504903A5 (US20040106767A1-20040603-C00005.png)
JP2017505293A5 (US20040106767A1-20040603-C00005.png)
JP2009501745A5 (US20040106767A1-20040603-C00005.png)
JP2014505107A5 (US20040106767A1-20040603-C00005.png)
JP2010511631A5 (US20040106767A1-20040603-C00005.png)
JP2012507535A5 (US20040106767A1-20040603-C00005.png)